News
Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...
The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...
Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...
Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 drugs ... respectively—to cap patients' monthly costs at $200.
13d
Pharmaceutical Technology on MSNWegovy and Zepbound costs capped at $200 in new Evernorth programmeEvernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...
Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...
Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...
Cigna’s (NYSE:CI) health services arm ... Zepbound. The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200 under the new offering. Patients can save as much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results